Efficacy and safety of subcutaneous tocilizumab in rheumatoid arthritis over 1 year: a UK real-world, open-label study

OBJECTIVE: The ACT-MOVE study assessed the real-world efficacy and safety of s.c. tocilizumab (TCZ-SC), provided as monotherapy or in combination with conventional synthetic DMARDs (csDMARDs) over 1 year, in patients with RA and an inadequate response to csDMARD therapy and/or first TNF inhibitor. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Isaacs, John D, Salih, Abdelrazig, Sheeran, Thomas, Patel, Yusuf I, Douglas, Karen, McKay, Neil D, Naisbett-Groet, Barbara, Choy, Ernest
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649953/
https://www.ncbi.nlm.nih.gov/pubmed/31431998
http://dx.doi.org/10.1093/rap/rkz010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649953/
https://www.ncbi.nlm.nih.gov/pubmed/31431998
http://dx.doi.org/10.1093/rap/rkz010

Ejemplares similares